Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3584]
Articles [92]
Editorials [5]
Conferences [157]
elearning [19]
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients...
Dr Mario Sznol - Yale Cancer Center New Haven, USA
Anti-PD-1 drug nivolumab shows high and durable clinical activity in patients with advanced melanoma ( Dr Mario Sznol - Yale Cancer Center New Haven, USA )
1 Jun 2013
Classification and immunohistochemical approach of intracranial germ cell...
Dr Ivo Leuschner - University Hospital of Schleswig-Holstein, Germany
Classification and immunohistochemical approach of intracranial germ cell tumours ( Dr Ivo Leuschner - University Hospital of Schleswig-Holstein, Germany )
29 May 2013
Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials
Dr Anna Vivancos - Vall d´Hebron Institute of Oncology, Barcelona, Spain
Biomarker analyses in emerging data from PI3K/AKT/mTOR programme clinical trials ( Dr Anna Vivancos - Vall d´Hebron Institute of Oncology, Barcelona, Spain )
16 May 2013
Integrating breast cancer genomics and proteomics
Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA
Integrating breast cancer genomics and proteomics ( Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA )
15 May 2013
Next wave of successful drug therapy strategies in HER2-positive breast cancer
Dr Hans Wildiers - University Hospital Leuven, Gasthuisberg, Belgium
Next wave of successful drug therapy strategies in HER2-positive breast cancer ( Dr Hans Wildiers - University Hospital Leuven, Gasthuisberg, Belgium )
15 May 2013
CD4 T cells in extensively inflitrated breast cancer signal organised immune...
Dr Karen Willard-Gallo - Université Libre de Bruxelles, Brussels, Belgium
CD4 T cells in extensively inflitrated breast cancer signal organised immune response and predict survival ( Dr Karen Willard-Gallo - Université Libre de Bruxelles, Brussels, Belgium )
15 May 2013
How do we design trials that improve outcome?
Dr Lisa Carey - University of North Carolina, Chapel Hill, USA
How do we design trials that improve outcome? ( Dr Lisa Carey - University of North Carolina, Chapel Hill, USA )
15 May 2013
The future of PI3K/AKT/mTOR inhibitors in breast cancer
Dr Sara Hurvitz - UCLA Santa Monica Hematology Oncology, USA
The future of PI3K/AKT/mTOR inhibitors in breast cancer ( Dr Sara Hurvitz - UCLA Santa Monica Hematology Oncology, USA )
15 May 2013
Update on the METABRIC consortium 2000 Breast Cancer Study
Prof Carlos Caldas - University of Cambridge, UK
Update on the METABRIC consortium 2000 Breast Cancer Study ( Prof Carlos Caldas - University of Cambridge, UK )
14 May 2013
Genetic alterations in postmenopausal women with hormone receptor-positive...
Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium
Genetic alterations in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
14 May 2013
Immunotherapy in melanoma and other cancers
Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA
Immunotherapy in melanoma and other cancers ( Dr Suzanne Topalian – Johns Hopkins, Baltimore, USA )
19 Apr 2013
Myeloma UK
Eric Low - Chief Executive, Myeloma UK
Myeloma UK ( Eric Low - Chief Executive, Myeloma UK )
6 Apr 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation